Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMRX Immuneering	$5.60 +7.9%	$3.83	$1.10 ▼ $6.18	$188.49M	0.37	848,538 shs	639,262 shs
IMTX Immatics	$5.28 -2.2%	$5.96	$3.30 ▼ $13.09	$656.37M	0.93	639,308 shs	324,860 shs
PROK ProKidney	$2.50 +0.4%	$2.42	$0.46 ▼ $7.13	$732.76M	1.76	2.41 million shs	989,584 shs
TBPH Theravance Biopharma	$13.97 +1.2%	$11.74	$7.88 ▼ $14.30	$694.99M	0.01	454,532 shs	486,498 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMRX Immuneering	-12.33%	+51.31%	+32.74%	+206.19%	+359.29%
IMTX Immatics	+0.93%	-3.57%	-19.04%	-0.74%	-50.59%
PROK ProKidney	+4.62%	+9.21%	-19.16%	+245.59%	+12.67%
TBPH Theravance Biopharma	0.00%	+3.06%	+24.77%	+48.39%	+64.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMRX Immuneering	3.54 of 5 stars	3.3	4.0	1.9	5.0	0.6
IMTX Immatics	2.1565 of 5 stars	3.4	3.0	2.0	1.7	0.0
PROK ProKidney	3.7222 of 5 stars	4.2	4.0	1.9	3.3	0.6
TBPH Theravance Biopharma	2.1024 of 5 stars	3.8	0.0	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMRX Immuneering	2.60	Moderate Buy	$13.00	131.85% Upside
IMTX Immatics	2.83	Moderate Buy	$14.67	179.58% Upside
PROK ProKidney	2.33	Hold	$6.25	151.51% Upside
TBPH Theravance Biopharma	3.50	Strong Buy	$21.33	52.98% Upside

Current Analyst Ratings Breakdown

Latest IMRX, PROK, TBPH, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
8/18/2025	PROK ProKidney	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	IMTX Immatics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/15/2025	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/14/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
6/18/2025	IMRX Immuneering	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $10.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMRX Immuneering	$320K	636.39	N/A	N/A	$0.80 per share	7.01
IMTX Immatics	$168.65M	3.78	$0.24 per share	21.90	$4.34 per share	1.21
PROK ProKidney	$80K	9,141.07	N/A	N/A	($3.41) per share	-0.73
TBPH Theravance Biopharma	$77.21M	9.10	N/A	N/A	$4.46 per share	3.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMRX Immuneering	-$61.04M	-$1.89	N/A	N/A	N/A	N/A	-146.28%	-117.22%	11/12/2025 (Estimated)
IMTX Immatics	$16.47M	-$0.65	N/A	N/A	N/A	-59.29%	-15.60%	-12.31%	N/A
PROK ProKidney	-$61.19M	-$0.57	N/A	N/A	N/A	N/A	N/A	-17.11%	11/11/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	$0.24	58.10	39.84	N/A	16.88%	6.93%	3.52%	11/11/2025 (Estimated)

Latest IMRX, PROK, TBPH, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	IMRX Immuneering	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/13/2025	Q1 2025	IMTX Immatics	-$0.38	-$0.66	-$0.28	-$0.66	$13.05 million	$6.48 million
8/12/2025	Q2 2025	PROK ProKidney	-$0.14	-$0.13	+$0.01	-$0.13	N/A	$0.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMRX Immuneering	N/A	3.70	3.70
IMTX Immatics	N/A	8.80	8.80
PROK ProKidney	N/A	11.48	11.48
TBPH Theravance Biopharma	N/A	6.70	6.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMRX Immuneering	67.65%
IMTX Immatics	64.41%
PROK ProKidney	51.59%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
IMRX Immuneering	22.90%
IMTX Immatics	3.30%
PROK ProKidney	41.49%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMRX Immuneering	60	36.32 million	28.00 million	Not Optionable
IMTX Immatics	260	121.55 million	117.54 million	Optionable
PROK ProKidney	3	294.28 million	172.18 million	Optionable
TBPH Theravance Biopharma	110	50.36 million	46.89 million	Optionable

IMRX, PROK, TBPH, and IMTX Headlines

Recent News About These Companies

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above 50 Day Moving Average - Here's Why

August 28 at 4:41 AM | marketbeat.com

Theravance Biopharma, Inc.: Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic ...

August 25 at 10:35 PM | finanznachrichten.de

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple ...

August 25 at 10:35 PM | finance.yahoo.com

Theravance Biopharma completes enrollment in CYPRESS study

August 25 at 12:32 PM | msn.com

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

August 25 at 6:00 AM | prnewswire.com

Theravance Biopharma Settles Patent Dispute with Cipla

August 20, 2025 | msn.com

Theravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High - Here's What Happened

August 20, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Upgraded at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen

August 17, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 3.4% - Here's Why

August 16, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High on Earnings Beat

August 14, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results

August 14, 2025 | marketbeat.com

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

August 13, 2025 | zacks.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Theravance Biopharma Inc (TBPH) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 13, 2025 | finance.yahoo.com

Theravance Biopharma reports Q2 EPS $1.08 with items, consensus (12c)

August 12, 2025 | msn.com

Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

August 12, 2025 | zacks.com

Theravance Bio: Q2 Earnings Snapshot

August 12, 2025 | timesunion.comT

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | prnewswire.com

Theravance Biopharma Q2 2025 Earnings Preview

August 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX, PROK, TBPH, and IMTX Company Descriptions

Immuneering NASDAQ:IMRX

$5.60 +0.41 (+7.90%)

Closing price 04:00 PM Eastern

Extended Trading

$5.60 0.00 (-0.09%)

As of 07:49 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Immatics NASDAQ:IMTX

$5.28 -0.12 (-2.22%)

Closing price 04:00 PM Eastern

Extended Trading

$5.27 -0.01 (-0.19%)

As of 05:10 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

ProKidney NASDAQ:PROK

$2.50 +0.01 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$2.49 -0.01 (-0.36%)

As of 07:57 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Theravance Biopharma NASDAQ:TBPH

$13.97 +0.17 (+1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$13.96 -0.01 (-0.04%)

As of 06:40 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time